The U.S. Food and Drug Administration (FDA) sent notice today about Abbott's decision to stop selling and distributing Trifecta aortic surgical heart valves in the U.S. market. This was an update to the February 2023 letter to healthcare providers about the potential risk of early structural valve deterioration (SVD) with Abbott Trifecta valves.
